Pfizer decision to withdrawal sickle cell drug leaves patients ... - STAT
WEBSept. 26, 2024. Pfizer’s decision Wednesday to pull its sickle cell pill off the market because of safety concerns shocked advocates and doctors, leaving many searching for answers and...
Sickle cell community scrambles after a Pfizer drug is pulled ... - STAT
WEB5 days ago · What the withdrawal of its sickle cell drug means for Pfizer, patients, and the FDA. The concerns behind the withdrawal were serious. The Food and Drug Administration approved Oxbryta in 2019, but ...
Pfizer withdraws sickle cell treatment due to safety concerns
WEB6 days ago · Pfizer has voluntarily withdrawn its sickle cell disease treatment Oxbryta (voxelotor) from the market due to safety concerns. The Food and Drug Administration (FDA) recommends clinicians stop prescribing the treatment and patients talk to their doctor about starting a different treatment. “I am disappointed as many other providers, patients and families (are),” said Banu Aygun, M.D., FAAP ...
MARAC Statement: Pfizer's Voxelotor (Oxbryta®) Withdrawal
WEB5 days ago · SCDAA Medical and Research Advisory Committee (MARAC) Statement: Pfizer’s Voxelotor (Oxbryta®) Withdrawal 9/27/24 What is the news? Pfizer announced the withdrawal of voxelotor (Oxbryta®) from national and global markets on September 25, 2024. Clinical research was also stopped. “Pfizer’s decision is based on the totality of clinical data that now indicate the overall benefit of […]
Regarding OXBRYTA ® - Sickle Cell Disease Association of …
WEBSep 26, 2024 · The Sickle Cell Disease Association of America, Inc., (SCDAA) is aware of the recent Pfizer announcement regarding the withdrawal of OXBRYTA ® (voxelotor) for the treatment of sickle cell in all markets. We await further information, and an SCDAA Medical and Research Advisory Committee (MARAC) statement will be forthcoming.
Pfizer's Withdrawal of SCD Drug Raises Questions - Medscape
WEB2 days ago · The global withdrawal of voxelotor (Oxbryta, Pfizer) has left clinicians who treat sickle cell disease (SCD) with the urgent task of reaching patients taking the medicine, while trying to ...
Sickle cell drug is withdrawn over safety concerns just ... - The BMJ
WEB2 days ago · The sickle cell treatment voxelotor (Oxbryta) has been withdrawn from all markets by the manufacturer Pfizer after a “higher than anticipated” number of deaths were reported and clinical evidence showed that the drug’s benefits no longer outweighed the risks. In a recall notice issued on 30 September the UK Medicines and Healthcare Products Regulatory Agency told clinicians and patients ...
Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease
WEBSep 25, 2024 · Risks and uncertainties include, among other things, uncertainties regarding the future of OXBRYTA (voxelotor), as well as uncertainties related to other sickle cell disease assets in our ...
Pfizer pulls sickle cell drug from market | Here & Now - WBUR
WEB1 day ago · Pfizer recalled Oxbryta and ended clinical trials over safety concerns, but sickle cell advocates are warning that stopping the drug abruptly could be dangerous.
EMA recommends suspension of sickle cell disease medicine Oxbryta
WEBSep 26, 2024 · Oxbryta is a medicine used to treat haemolytic anaemia (excess breakdown of red blood cells) in patients aged 12 years and older who have sickle cell disease. Oxbryta can be given on its own or together with another medicine for sickle cell disease called hydroxycarbamide. It contains the active substance voxelotor.